Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Mortality among Parkinson's disease patients treated with pimavanserin or atypical antipsychotics: an observational study in Medicare beneficiaries

Abstract

OBJECTIVE: antagonist, is indicated for treatment of hallucinations and delusions associated with Parkinson's disease psychosis. In premarketing trials in patients with Parkinson's disease psychosis, 11% of patients died during open-label pimavanserin treatment. Antipsychotics, which are used off-label in Parkinson's disease psychosis, increase mortality in dementia patients. The authors compared mortality with pimavanserin and atypical antipsychotics in a large database. METHODS: This was a retrospective new-user cohort study of Medicare beneficiaries with Parkinson's disease initiating pimavanserin (N=3,227) or atypical antipsychotics (N=18,442) from April 2016 to March 2019. All-cause mortality hazard ratios and 95% confidence intervals were estimated for pimavanserin compared with atypical antipsychotics, using segmented proportional hazards regression over 1-180 and 181+ days of treatment. Potential confounding was addressed through inverse probability of treatment weighting (IPTW). RESULTS: Pimavanserin users had a mean age of approximately 78 years, and 45% were female. Before IPTW, some comorbidities were more prevalent in atypical antipsychotic users; after IPTW, comorbidities were well balanced between groups. In the first 180 days of treatment, mortality was approximately 35% lower with pimavanserin than with atypical antipsychotics (hazard ratio=0.65, 95% CI=0.53, 0.79), with approximately one excess death per 30 atypical antipsychotic-treated patients; however, during treatment beyond 180 days, there was no additional mortality advantage with pimavanserin (hazard ratio=1.05, 95% CI=0.82, 1.33). Pimavanserin showed no mortality advantage in nursing home patients. CONCLUSIONS: Pimavanserin use was associated with lower mortality than atypical antipsychotic use during the first 180 days of treatment, but only in community-dwelling patients, not nursing home residents.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.21090876

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Research works printed but not linked: 1

  1. Pennap D, 2020, Pharmacoepidemiol Drug Saf, 29, 401

Cited by

See all 33

Metadata

Authors
Mosholder, A. D., Ma, Y., Akhtar, S., Podskalny, G. D., Feng, Y., Lyu, H., Liao, J., Wei, Y., Wernecke, M., Leishear, K., Nelson, L. M., MaCurdy, T. E., Kelman, J. A., & Graham, D. J.
Affiliations
United States Food and Drug Administration (US)
Venue
American Journal of Psychiatry
Published
2022-08-01
Volume
179
Issue
8
Pages
553-561
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W4282958777
Cited by
33
References
21
Citations by year
2026: 2 · 2025: 6 · 2024: 11 · 2023: 7 · 2022: 7
FWCI
4.08
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
Keywords
pimavanserin, atypical antipsychotics, Parkinson's disease psychosis, mortality, all-cause mortality, delusions and hallucinations, nursing home residents, community-dwelling patients, inverse probability of treatment weighting, Medicare beneficiaries
MeSH terms
Aged, Female, Medicare, Humans, Male, Parkinson Disease, Piperidines, Psychotic Disorders, Retrospective Studies, Antipsychotic Agents, United States, Urea, Cohort Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mortality among Parkinson's disease patients treated with pimavanserin or atypical antipsychotics: an observational study in Medicare beneficiaries. https://app.cochat.ai/papers/10.1176/appi.ajp.21090876
The paper
Mosholder, A. D., Ma, Y., Akhtar, S., Podskalny, G. D., Feng, Y., Lyu, H., Liao, J., Wei, Y., Wernecke, M., Leishear, K., Nelson, L. M., MaCurdy, T. E., Kelman, J. A., & Graham, D. J. (2022). Mortality among Parkinson's disease patients treated with pimavanserin or atypical antipsychotics: an observational study in Medicare beneficiaries. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.21090876

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.